CELL INTELLIGENCE · 肿瘤细胞治疗研究

胶质母细胞瘤的代谢与翻译后脆弱性：二硫死亡、糖基化及对 CAR-T 治疗的启示

Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.

利用旁分泌 SIRPγ 衍生的 CD47 阻断剂增强抗 EGFRvIII CAR-T 细胞治疗对胶质母细胞瘤的疗效

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker.

重复外周输注抗 EGFRvIII CAR-T 细胞联合帕博利珠单抗在胶质母细胞瘤中未见疗效：1 期试验

Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.

胶质母细胞瘤的 CAR-T 细胞治疗：来自数学建模的启示

CAR-T cell therapy for glioblastoma: insight from mathematical modeling.

本研究提出了一个针对胶质母细胞瘤 CAR-T 细胞治疗的综合性建模框架，强调了给药方案和耐药动态的重要性。研究结果为优化治疗策略以改善患者预后提供了有价值的指导。

CAR-T 细胞疗法治疗胶质母细胞瘤：分子靶点与治疗策略的系统综述

CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.

胶质母细胞瘤免疫治疗：当前策略与进展前景的系统综述

Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.

胶质母细胞瘤中的 CAR-T 细胞：当前认识与有前景的未来

Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.

酪氨酸激酶抑制剂处理胶质母细胞瘤细胞后 EGFRvIII 表位可及性增加为免疫治疗带来更多机会

Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy.

EGFRvIII 阳性胶质母细胞瘤细胞系的表型可塑性及 TGF-β 与 EGF 对这些细胞的多向影响——EGFRvIII 似为弱致癌基因

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells-EGFRvIII Ap

TGF 和 EGF 在 EGFRvIII 背景下的作用仍不明确。

用于实体瘤中 T 细胞募集的双特异性 T 细胞衔接器：文献综述

Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review.